Abstract:Mitochondria play an important and multifaceted role in cellular function, catering to the cell's energy and biosynthetic requirements. They modulate apoptosis while responding to diverse extracellular and intracellular stresses including reactive oxygen species (ROS), nutrient and oxygen scarcity, endoplasmic reticulum stress, and signaling via surface death receptors. Integral components of mitochondria, such as mitochondrial DNA (mtDNA), mitochondrial RNA (mtRNA), Adenosine triphosphate (ATP), cardiolipin, and formyl peptides serve as major damage-associated molecular patterns (DAMPs). These molecules activate multiple innate immune pathways both in the cytosol [such as Retionoic Acid-Inducible Gene-1 (RIG-1) and Cyclic GMP-AMP Synthase (cGAS)] and on the cell surface [including Toll-like receptors (TLRs)]. This activation cascade leads to the release of various cytokines, chemokines, interferons, and other inflammatory molecules and oxidative species. The innate immune pathways further induce chronic inflammation in the tumor microenvironment which either promotes survival and proliferation or promotes epithelial to mesenchymal transition (EMT), metastasis and therapeutic resistance in the cancer cell's. Chronic activation of innate inflammatory pathways in tumors also drives immunosuppressive checkpoint expression in the cancer cells and boosts the influx of immune-suppressive populations like Myeloid-Derived Suppressor Cells (MDSCs) and Regulatory T cells (Tregs) in cancer. Thus, sensing of cellular stress by the mitochondria may lead to enhanced tumor growth. In addition to that, the tumor microenvironment also becomes a source of immunosuppressive cytokines. These cytokines exert a debilitating effect on the functioning of immune effector cells, and thus foster immune tolerance and facilitate immune evasion. Here we describe how alteration of the mitochondrial homeostasis and cellular stress drives innate inflammatory pathways in the tumor microenvironment.

Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression

Research Progress on Mitochondria Regulating Tumor Immunity.

Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling

Manipulating mitochondrial electron flow enhances tumor immunogenicity

Targeting mitochondrial damage: shining a new light on immunotherapy

Mitochondria-Shaping Proteins and Chemotherapy

Surface Molecularly Engineered Mitochondria Conduct Immunophenotype Repolarization of Tumor-Associated Macrophages to Potentiate Cancer Immunotherapy

Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity

Mitochondria targeted metabolic inhibitors promote lymphocyte infiltration into murine pancreatic tumors

Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8 + T cell metabolic fitness and function in tumors

Epigenetic Induction of Mitochondrial Fission Is Required for Maintenance of Liver Cancer–Initiating Cells

Mitochondrial Dynamics Controls Anti-Tumour Innate Immunity by Regulating CHIP-IRF1 Axis Stability

In Situ Vaccination with Mitochondria‐Targeting Immunogenic Death Inducer Elicits CD8+ T Cell‐Dependent Antitumor Immunity to Boost Tumor Immunotherapy

Mitochondria in tumor immune surveillance and tumor therapies targeting mitochondria

Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance

Mitochondrial dynamics and colorectal cancer biology: mechanisms and potential targets

Mitochondria driven innate immune signaling and inflammation in cancer growth, immune evasion, and therapeutic resistance

Mitochondrial regulation in the tumor microenvironment: targeting mitochondria for immunotherapy

Impact of mitochondrial dysfunction on the antitumor effects of immune cells

A membrane-associated MHC-I inhibitory axis for cancer immune evasion

Mitochondrial dynamics as a potential therapeutic target in acute myeloid leukemia